ArsenalBio reaches next stage of maturity with BMS deal

In its first deal with a major pharma, ArsenalBio will put its synthetic biology toolkit to the test in creating programmable T cell therapies against solid tumor targets chosen by BMS.

ArsenalBio as among the first companies to originate from the Parker Institute for Cancer Immunotherapy (PICI) and embodied the institute’s aim of bringing investigators and technologies from different academic research centers under one roof. ...